Companion Animal Safety Assessments
Aug 30, 2021
2 minutes Read
Animal Health
Attentive Science has been providing early discovery toxicology, formulation/PK screening studies, MTD/Subchronic toxicity studies as well as Safety Pharmacology services to the biotechnology and pharmaceutical companies to support the advancement of new human therapies. A field of research that sometimes goes unnoticed is the need for safety assessment of Companion Animal therapeutics.
There are fundamental differences between human and companion animal therapeutic safety testing. Members of the Attentive Science team have extensive experience performing Bioequivalence Studies and Guideline 185 Target Animal Safety for Veterinary Pharmaceutical (VICH GL 43, April 2009) studies in appropriate test systems conducted under the principles of Good Laboratory Practices (GLP).
The primary goal at Attentive Science is to make sure the studies are conducted to the highest quality and to achieve the objectives of the study to ensure the therapeutic is approved by the FDA’s Center for Veterinary Medicine (CVM). To ensure these goals are accomplished, Attentive Science will partner with you the client to help with pre-study meetings with the CVM, if needed. Additionally, our scientist will design programs (supplying draft study protocols) that can be used during meetings with the agency to ensure the approach is accepted prior to the conduct of the study.
Our Kansas location places us in the heart of the Animal Health Corridor and the site is only 25 minutes south from where the annual conference is held. Members of the management team have been involved in the Annual Animal Health conference for many years and have therefore built a strong understanding of the trends within the field of safety assessment of Companion Animal therapeutics. We look forward to once again having a presence within the Animal Health Corridor to facilitate the advancement of animal care and support.
Contact Us and let us show you how we can help.
Social Networks
Tags
MTD/Subchronic
formulation/PK
screening studies